Disney Walt Co (DIS) Share Value Declined While Blue Edge Capital Has Decreased Its Stake; Idexx Labs Com (IDXX) Share Price Rose While Capital Counsel Has Upped by $1.51 Million Its Position

May 22, 2018 - By Richard Conner

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Logo

Capital Counsel Llc increased its stake in Idexx Labs Inc Com (IDXX) by 1.32% based on its latest 2017Q4 regulatory filing with the SEC. Capital Counsel Llc bought 9,666 shares as the company’s stock rose 21.09% while stock markets declined. The institutional investor held 742,729 shares of the health care company at the end of 2017Q4, valued at $116.15 million, up from 733,063 at the end of the previous reported quarter. Capital Counsel Llc who had been investing in Idexx Labs Inc Com for a number of months, seems to be bullish on the $17.37B market cap company. The stock decreased 0.60% or $1.2 during the last trading session, reaching $199.99. About 241,127 shares traded. IDEXX Laboratories, Inc. (NASDAQ:IDXX) has risen 23.99% since May 22, 2017 and is uptrending. It has outperformed by 12.44% the S&P500.




Blue Edge Capital Llc decreased its stake in Disney Walt Co (DIS) by 2.37% based on its latest 2017Q4 regulatory filing with the SEC. Blue Edge Capital Llc sold 70 shares as the company’s stock declined 8.57% with the market. The institutional investor held 2,886 shares of the television services company at the end of 2017Q4, valued at $310.29M, down from 2,956 at the end of the previous reported quarter. Blue Edge Capital Llc who had been investing in Disney Walt Co for a number of months, seems to be less bullish one the $155.12B market cap company. The stock increased 0.01% or $0.01 during the last trading session, reaching $104.07. About 6.96 million shares traded. The Walt Disney Company (NYSE:DIS) has declined 11.59% since May 22, 2017 and is downtrending. It has underperformed by 23.14% the S&P500.

Among 11 analysts covering IDEXX Laboratories (NASDAQ:IDXX), 7 have Buy rating, 2 Sell and 2 Hold. Therefore 64% are positive. IDEXX Laboratories had 29 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was maintained by Canaccord Genuity with “Buy” on Thursday, July 23. Canaccord Genuity maintained it with “Buy” rating and $18000 target in Tuesday, June 13 report. The firm has “Market Perform” rating by Raymond James given on Friday, August 28. The rating was maintained by Canaccord Genuity on Monday, May 7 with “Buy”. The stock has “Buy” rating by Stifel Nicolaus on Thursday, February 1. Canaccord Genuity maintained IDEXX Laboratories, Inc. (NASDAQ:IDXX) rating on Thursday, October 5. Canaccord Genuity has “Buy” rating and $180.0 target. The stock of IDEXX Laboratories, Inc. (NASDAQ:IDXX) earned “Outperform” rating by Credit Suisse on Wednesday, April 13. The firm earned “Buy” rating on Wednesday, August 23 by Bank of America. The stock of IDEXX Laboratories, Inc. (NASDAQ:IDXX) earned “Buy” rating by Canaccord Genuity on Monday, August 21. The stock of IDEXX Laboratories, Inc. (NASDAQ:IDXX) earned “Buy” rating by C.L. King on Friday, July 28.

Capital Counsel Llc, which manages about $2.48B and $1.22B US Long portfolio, decreased its stake in Wabtec Corp Com (NYSE:WAB) by 35,779 shares to 831,967 shares, valued at $67.75M in 2017Q4, according to the filing. It also reduced its holding in Core Laboratories N V Com (NYSE:CLB) by 23,123 shares in the quarter, leaving it with 86,999 shares, and cut its stake in Varian Med Sys Inc (NYSE:VAR).

More recent IDEXX Laboratories, Inc. (NASDAQ:IDXX) news were published by: Fool.com which released: “IDEXX Laboratories Barks Out Another Successful Quarter” on May 11, 2018. Also Seekingalpha.com published the news titled: “Buy Diamondback Energy On Declines – Cramer’s Lightning Round (5/11/18)” on May 14, 2018. Fool.com‘s news article titled: “The 3 Stocks on the MFM Team’s Radar This Week” with publication date: May 10, 2018 was also an interesting one.

Since January 9, 2018, it had 2 insider buys, and 7 insider sales for $23.44 million activity. END WILLIAM T sold $737,939 worth of IDEXX Laboratories, Inc. (NASDAQ:IDXX) on Thursday, February 22. $179,580 worth of stock was bought by Claflin Bruce L. on Wednesday, February 7. $178,045 worth of IDEXX Laboratories, Inc. (NASDAQ:IDXX) was bought by Kingsley Lawrence D. $565,232 worth of IDEXX Laboratories, Inc. (NASDAQ:IDXX) was sold by JUNIUS DANIEL M. $1.20M worth of IDEXX Laboratories, Inc. (NASDAQ:IDXX) was sold by MCKEON BRIAN P.

Investors sentiment decreased to 0.81 in Q4 2017. Its down 0.05, from 0.86 in 2017Q3. It dropped, as 30 investors sold IDXX shares while 217 reduced holdings. 64 funds opened positions while 137 raised stakes. 72.13 million shares or 17.89% less from 87.85 million shares in 2017Q3 were reported. Seaward Management Partnership, Massachusetts-based fund reported 9,680 shares. Dorsey Wright Assoc invested in 0.48% or 16,920 shares. Sun Life holds 0% of its portfolio in IDEXX Laboratories, Inc. (NASDAQ:IDXX) for 190 shares. Scotia, a Ontario – Canada-based fund reported 3,653 shares. Federated Investors Pa reported 674,691 shares stake. Maryland-based Chevy Chase Tru Holdings has invested 0.05% in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Bridgecreek Investment Mgmt Limited Liability accumulated 66,090 shares or 2.43% of the stock. Cornerstone Cap Mgmt Ltd Liability Com holds 0.02% of its portfolio in IDEXX Laboratories, Inc. (NASDAQ:IDXX) for 16,398 shares. Zebra Mngmt invested in 0.17% or 3,177 shares. Robeco Institutional Asset Mgmt Bv holds 161,963 shares. Oakbrook Invests Ltd Liability Corporation reported 0.04% in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Rafferty Asset Management Limited Liability Company holds 9,405 shares or 0.03% of its portfolio. Raymond James & Assoc reported 25,567 shares stake. Hillsdale Invest Mgmt, a Ontario – Canada-based fund reported 2,160 shares. First Quadrant Lp Ca reported 205,052 shares.

Analysts await The Walt Disney Company (NYSE:DIS) to report earnings on August, 14. They expect $1.98 earnings per share, up 25.32% or $0.40 from last year’s $1.58 per share. DIS’s profit will be $2.95 billion for 13.14 P/E if the $1.98 EPS becomes a reality. After $1.84 actual earnings per share reported by The Walt Disney Company for the previous quarter, Wall Street now forecasts 7.61% EPS growth.

Among 39 analysts covering The Walt Disney Company (NYSE:DIS), 24 have Buy rating, 1 Sell and 14 Hold. Therefore 62% are positive. The Walt Disney Company had 156 analyst reports since July 24, 2015 according to SRatingsIntel. Macquarie Research upgraded the stock to “Outperform” rating in Wednesday, August 10 report. The firm has “Buy” rating given on Friday, July 24 by Topeka Capital Markets. The stock has “Outperform” rating by Credit Suisse on Tuesday, November 10. The firm has “Sell” rating by BMO Capital Markets given on Wednesday, November 22. The firm earned “Hold” rating on Wednesday, August 9 by Needham. The firm has “Buy” rating given on Sunday, September 24 by Piper Jaffray. The stock of The Walt Disney Company (NYSE:DIS) has “Overweight” rating given on Tuesday, October 31 by Morgan Stanley. On Friday, October 13 the stock rating was maintained by Barclays Capital with “Equal-Weight”. Pivotal Research initiated it with “Hold” rating and $106 target in Tuesday, October 20 report. The firm has “Market Perform” rating given on Thursday, August 20 by Bernstein.

Since February 26, 2018, it had 0 insider buys, and 1 sale for $194,780 activity.

Blue Edge Capital Llc, which manages about $153.03 million and $250.40B US Long portfolio, upped its stake in Deere & Co (NYSE:DE) by 4,662 shares to 11,119 shares, valued at $1.74 billion in 2017Q4, according to the filing. It also increased its holding in Vanguard Reit (VNQ) by 987 shares in the quarter, for a total of 9,766 shares, and has risen its stake in Ishares Msci Acwi Ex Us (ACWX).

The Walt Disney Company (NYSE:DIS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts